Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
Recruiting now · Phase 1/Phase 2
Conditions studied: HIV-1-infection
In brief
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Key facts
- Study ID
- NCT05660980
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 90
- Starts
- 2024-01-24
- Expected to finish
- 2029-03-31
- Last updated by the study team
- 2026-05-19
Who can join
Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site 5030, Emory University School of Medicine NICHD CRS — Atlanta, Georgia, United States (enrolling)
- Site 6501, St. Jude Children's Research Hospital CRS — Memphis, Tennessee, United States (enrolling)
- Site 12701, Gaborone CRS — Gaborone, Botswana (enrolling)
- Site 12702, Molepolole CRS — Gaborone, Botswana (enrolling)
- Site 5073, SOM Federal University Minas Gerais Brazil NICHD CRS — Belo Horizonte, Brazil (enrolling)
- CRS 5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site — Rio de Janeiro, Brazil (enrolling)
- Site 30300 Umlazi CRS Site — Umlazi, KwaZulu-Natal, South Africa (enrolling)
- CRS 8052, Soweto IMPAACT — Johannesburg, South Africa (enrolling)
- Site 8051, Wits RHI Shandukani Research Centre CRS — Johannesburg, South Africa (enrolling)
- Siriraj Hospital, Mahidol University NICHD CRS (Site #5115) — Bangkok, Bangkoknoi, Thailand (enrolling)
- CRS 31784, Chiang Mai University HIV Treatment CRS — Chiang Mai, Thailand (enrolling)
- Site 5116, Chiangrai Prachanukroh Hospital NICHD CRS — Chiang Rai, Thailand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.